| Malignant neoplasm of breast
Talzenna vs Aromasin
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.Deep comparison between: Talzenna vs Aromasin with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAromasin has a higher rate of injection site reactions vs Talzenna based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Aromasin but not Talzenna, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Talzenna
Aromasin
At A Glance
Oral
Daily
PARP inhibitor
Oral
Daily
Aromatase inactivator
Indications
- Malignant neoplasm of breast
- Hormone refractory prostate cancer
- Malignant neoplasm of breast
- Advanced breast cancer
Dosing
Malignant neoplasm of breast 1 mg orally once daily until disease progression or unacceptable toxicity.
Hormone refractory prostate cancer 0.5 mg orally once daily with enzalutamide until disease progression or unacceptable toxicity; patients should also receive a GnRH analog concurrently or have had bilateral orchiectomy.
Malignant neoplasm of breast, Advanced breast cancer 25 mg orally once daily after a meal; increase to 50 mg once daily after a meal when administered with a strong CYP 3A4 inducer.
Contraindications
—
- Known hypersensitivity to exemestane or any excipient
Adverse Reactions
Most common (>=20%) Fatigue, nausea, vomiting, diarrhea, headache, alopecia, decreased appetite, hemoglobin decreased, neutrophils decreased, lymphocytes decreased, platelets decreased
Serious Anemia, pyrexia
Most common (>=10%) Hot flushes, fatigue, arthralgia, headache, insomnia, increased sweating
Serious Cardiac ischemic events (myocardial infarction, angina, myocardial ischemia), cardiac failure, clinical fractures
Postmarketing Hypersensitivity, hepatitis including cholestatic hepatitis, paresthesia, tendon disorders including tendon rupture and tendonitis and tenosynovitis, acute generalized exanthematous pustulosis, urticaria, pruritus
Pharmacology
Talazoparib is an inhibitor of PARP enzymes (PARP1 and PARP2) involved in DNA repair; it induces cytotoxicity in cancer cells with DNA repair gene defects through inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage, decreased cell proliferation, and apoptosis.
Aromatase inactivator; exemestane is an irreversible steroidal aromatase inactivator that acts as a false substrate for the aromatase enzyme, binding irreversibly to the active site ('suicide inhibition') and significantly lowering circulating estrogen concentrations in postmenopausal women without affecting adrenal corticosteroid or aldosterone biosynthesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Talzenna
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
Aromasin
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Talzenna
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (4/8)
Aromasin
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Talzenna
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Aromasin
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Talzenna.
$0/fillfill
Aromasin Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TalzennaView full Talzenna profile
AromasinView full Aromasin profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.